Equity · Healthcare
DexCom, Inc. (DXCM) perpetual futures
DexCom, Inc. is a medical technology company that develops and markets continuous glucose monitoring (CGM) systems for people with diabetes and healthcare practitioners in the US and internationally.
Price chart
Interactive TradingView chart
TradingView symbol NASDAQ:DXCM
Loads TradingView's third-party widget (about 1 MB) on demand.
Trading data
Perpetual market activity
0/1 live markets
Trading data
Perpetual market activity
Spot performance
BingXBest venues for this underlying
Best liquidity
-Tightest spread
-Highest volume
-Next catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average price target | $97.85 |
| Target range (low – high) | $86 – $115 |
| Ratings counted | 53 |
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 4 | 22 | 3 | 0 | 0 |
| Oct 2026 | 4 | 22 | 3 | 0 | 0 |
| Sep 2026 | 3 | 22 | 3 | 0 | 0 |
| Aug 2026 | 3 | 22 | 3 | 0 | 0 |
| Jul 2026 | 3 | 22 | 3 | 0 | 0 |
| Jun 2026 | 3 | 22 | 3 | 0 | 0 |
| May 2026 | 4 | 21 | 3 | 0 | 1 |
| Apr 2026 | 4 | 20 | 2 | 0 | 1 |
| Mar 2026 | 5 | 21 | 3 | 0 | 1 |
| Feb 2026 | 5 | 20 | 3 | 0 | 1 |
| Jan 2026 | 5 | 20 | 4 | 0 | 1 |
| Dec 2025 | 5 | 20 | 5 | 0 | 0 |
Ownership
Institutional · 2026-Q3Reference market activity
DXCM-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25DexCom officer Michael Jon Brown reported disposing of 1,451 common shares on 2026-11-08 via F-InKind code (tax withholding), at $79.41 per share, leaving 96,734 shares owned.
DexCom CEO Jacob Steven Leach had 1,451 common shares withheld for taxes at $79.41 each (F-InKind, 2026-11-08), leaving 417,457 shares owned.
DexCom officer Sadie Stern disposed of 1,451 common shares at $79.41 through tax withholding (Code F), leaving 119,462 shares held.
DexCom officer Sylvain Jereme M had 1,451 shares of common stock withheld at $79.41 for tax obligations (code F) on Nov 8, 2026, leaving 145,377 shares owned.
Ashley Euan A., a DexCom director, reported a gift (G) of 2,389 common shares at a $0.00 value on 2026-10-30, leaving 10,342 shares directly owned.
DexCom officer Sadie Stern sold 2,565 shares of Common Stock on the open market at $78.62 per share on 2026-10-27, leaving 120,913 shares owned.
DexCom officer Brown Michael Jon (EVP Chief Legal Compliance Off) sold 1,700 common shares at $85.48 on Oct 15, 2026, leaving 98,185 shares owned.
DexCom officer Sadie Stern sold 2,565 common shares on the open market at $86.15 on 2026-09-28, leaving 123,478 shares owned.
Director Nicholas Augustinos sold 8,089 DexCom common shares on Sept 14-15, 2026 at $84.02-$84.04, leaving 29,293 shares owned.
DexCom officer Brown Michael Jon sold 1,700 shares of Common Stock at $84.04 apiece, leaving 99,885 shares owned.
DexCom officer Sylvain Jereme M sold 3,638 common shares at $83.27 on Sept 10, 2026, leaving 146,828 shares owned.
DexCom director Glenn S Boehnlein received an award of 5,841 shares of Common Stock on 2026-09-10, bringing his holdings to 5,841 shares. This was a compensation grant, not a purchase.
DexCom director Glenn S Boehnlein filed an initial Form 3 on 2026-09-10, reporting 42 shares of Common Stock held directly. No purchase or sale occurred.
DexCom officer Sadie Stern sold 2,565 common shares at $88.37 on Aug 27, 2026, leaving 126,043 shares owned.
DexCom CEO Jacob Steven Leach had 1,451 shares of Common Stock withheld for tax at $92.34 each on Aug 22, 2026, leaving 418,908 shares owned.
DexCom officer Sylvain Jereme M reported 1,451 common shares disposed via F-Tax withholding at $92.34 per share on 2026-08-22, leaving 150,390 shares owned.
DexCom officer Brown Michael Jon reported 1,451 shares of Common Stock withheld for tax at $92.34 per share, leaving 101,502 shares owned.
DexCom officer Sadie Stern disposed 1,451 Common Stock shares for tax withholding at $92.34 per share (F-Tax), leaving 128,608 shares owned.
DexCom director and Executive Chair Kevin R. Sayer sold 26,756 common shares in 3 open-market transactions on 2026-08-20 at prices from $89.706 to $91.41, leaving 302,214 shares owned afterward.
DexCom officer Brown Michael Jon sold 1,700 common shares at $91.93 per share on 2026-08-14, leaving 102,953 shares owned after the sale.
DexCom director Nicholas Augustinos gifted 1,075 common shares on 2026-08-12, leaving 37,382 shares owned after the transaction.
DexCom director Bridgette P. Heller sold 1,012 shares of Common Stock in an open-market sale at $88.29 each for about $89,350, leaving 29,570 shares. (Form 4, filed 2026-08-13.)
Filings
41 · Latest SEC filingsDexCom CEO Jacob Steven Leach had 1,451 common shares withheld for taxes at $79.41 each (F-InKind, 2026-11-08), leaving 417,457 shares owned.
DexCom officer Michael Jon Brown reported disposing of 1,451 common shares on 2026-11-08 via F-InKind code (tax withholding), at $79.41 per share, leaving 96,734 shares owned.
DexCom officer Sadie Stern disposed of 1,451 common shares at $79.41 through tax withholding (Code F), leaving 119,462 shares held.
DexCom officer Sylvain Jereme M had 1,451 shares of common stock withheld at $79.41 for tax obligations (code F) on Nov 8, 2026, leaving 145,377 shares owned.
Ashley Euan A., a DexCom director, reported a gift (G) of 2,389 common shares at a $0.00 value on 2026-10-30, leaving 10,342 shares directly owned.
DexCom officer Sadie Stern sold 2,565 shares of Common Stock on the open market at $78.62 per share on 2026-10-27, leaving 120,913 shares owned.
DexCom officer Brown Michael Jon (EVP Chief Legal Compliance Off) sold 1,700 common shares at $85.48 on Oct 15, 2026, leaving 98,185 shares owned.
DexCom officer Sadie Stern sold 2,565 common shares on the open market at $86.15 on 2026-09-28, leaving 123,478 shares owned.
Director Nicholas Augustinos sold 8,089 DexCom common shares on Sept 14-15, 2026 at $84.02-$84.04, leaving 29,293 shares owned.
DexCom officer Brown Michael Jon sold 1,700 shares of Common Stock at $84.04 apiece, leaving 99,885 shares owned.
DexCom officer Sylvain Jereme M sold 3,638 common shares at $83.27 on Sept 10, 2026, leaving 146,828 shares owned.
DexCom director Glenn S Boehnlein filed an initial Form 3 on 2026-09-10, reporting 42 shares of Common Stock held directly. No purchase or sale occurred.
DexCom director Glenn S Boehnlein received an award of 5,841 shares of Common Stock on 2026-09-10, bringing his holdings to 5,841 shares. This was a compensation grant, not a purchase.
DexCom officer Sadie Stern sold 2,565 common shares at $88.37 on Aug 27, 2026, leaving 126,043 shares owned.
DexCom officer Sadie Stern disposed 1,451 Common Stock shares for tax withholding at $92.34 per share (F-Tax), leaving 128,608 shares owned.
DexCom officer Sylvain Jereme M reported 1,451 common shares disposed via F-Tax withholding at $92.34 per share on 2026-08-22, leaving 150,390 shares owned.
DexCom officer Brown Michael Jon reported 1,451 shares of Common Stock withheld for tax at $92.34 per share, leaving 101,502 shares owned.
DexCom CEO Jacob Steven Leach had 1,451 shares of Common Stock withheld for tax at $92.34 each on Aug 22, 2026, leaving 418,908 shares owned.
DexCom director and Executive Chair Kevin R. Sayer sold 26,756 common shares in 3 open-market transactions on 2026-08-20 at prices from $89.706 to $91.41, leaving 302,214 shares owned afterward.
DexCom officer Brown Michael Jon sold 1,700 common shares at $91.93 per share on 2026-08-14, leaving 102,953 shares owned after the sale.
DexCom director Bridgette P. Heller sold 1,012 shares of Common Stock in an open-market sale at $88.29 each for about $89,350, leaving 29,570 shares. (Form 4, filed 2026-08-13.)
DexCom director Nicholas Augustinos gifted 1,075 common shares on 2026-08-12, leaving 37,382 shares owned after the transaction.
DexCom director Mark G. Foletta sold 4,000 common shares in two open-market sales on July 31 and August 3, 2026, at prices of $80.00-$85.32, leaving 48,852 shares owned.
DexCom director Kevin R. Sayer sold 26,756 common shares at $76.3193 on July 20, 2026, leaving 328,970 shares owned.
DexCom officer Brown Michael Jon reported selling 1,700 shares of Common Stock at $74.42 per share, leaving 104,653 shares owned after the sale.
Director Kevin R. Sayer (Executive Chair) sold 26,756 DexCom common shares at $72 on July 6, 2026, leaving 355,726 shares held.
DexCom officer Brown Michael Jon sold 1,700 common shares at $75.55 on 2026-06-15, leaving 106,353 shares owned.
Director Mark G. Foletta sold 4,000 DexCom common shares on June 15, 2026, in two open-market sales at prices from $74.0991 to $74.8187, leaving 52,852 shares owned.
DexCom officer Jon Coleman sold 9,823 common shares on June 3-4, 2026 at $73-$74.13, leaving 95,450 shares owned.
DexCom director Heller Bridgette P received an award of 5,575 shares of Common Stock on 2026-05-28 (A-Award, $0.00), bringing her direct holdings to 30,582 shares, per a Form 4 filed 2026-06-01.
Director Nicholas Augustinos received a grant (A-Award) of 5,575 shares of DexCom common stock on May 28, 2026, at $0.00, leaving him with 5,575 shares owned. This is compensation, not an open-market purchase.
DexCom director Malady Kyle received an award of 5,575 common shares (A-Award) on 2026-05-28, at $0.00, leaving 28,242 shares owned. This is a grant/compensation, not an open-market purchase.
DexCom director Steven R. Altman received 5,565 shares of Common Stock as a compensation award on May 28, 2026, at $0.00 per share, bringing his holdings to 5,565 shares.
DexCom director Mark G. Foletta received a stock award of 6,331 common shares at $0.00 on 2026-05-28, leaving him with 6,331 shares owned. The Form 4 was filed 2026-06-01.
Transcripts
PendingCompany news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.Company data
Company intelligence
Updated: Nov 2, 2026, 05:36 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Medical - Devices
- Chief executive
- Jacob Steven Leach
- Employees
- 11,050
- IPO date
- Apr 14, 2005
- Country
- US
- Exchange
- NASDAQ Global Select
Rating factors
- Return on equityi
- 5
- Return on assetsi
- 5
- Debt to equityi
- 2
- Price to earningsi
- 2
- Price to booki
- 1
Company press releases
Congressional disclosures
Senate
House
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VTI | 0.04% | 12M |
| VOO | 0.05% | 9.9M |
| VO | 0.32% | 8.1M |
| QQQ | 0.13% | 7.9M |
| FXAIX | 0.05% | 5.1M |
| VUG | 0.11% | 5M |
| IVV | 0.05% | 5M |
| 1655.T | 0.05% | 5M |
| XSP.TO | 0.04% | 5M |
| SPY | 0.05% | 4.6M |
| VGHAX | 0.71% | 3.1M |
| VOT | 0.77% | 3M |
Analyst track record
How the analysts covering DXCM have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 150 | 459 |
| Analysts | 36 | 40 |
| Buy / hold / sell | 139 / 8 / 3 | 417 / 39 / 3 |
| Upgrades / downgrades / initiations | 1 / 0 / 4 | 4 / 3 / 11 |
| Price targets hit / missed | 18 / 120 (13%) | 27 / 397 (6%) |
| Avg. return after a rating (TipRanks) | -9.3% | -19.6% |
| Best / worst call | +26.1% / -33.8% | +26.1% / -53.3% |
After buy calls on this stock: median 21-day move +1.6% (n = 421) vs S&P 500 +1.1% (n = 420)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Mike KratkyLeerink Partners41% hit rate on this stock · 17 targets measuredBuytarget $84.00Oct 14, 2025
- William PlovanicCanaccord Genuity39% hit rate on this stock · 18 targets measuredBuytarget $97.00Oct 30, 2026
- Matthew O'BrienPiper Sandler35% hit rate on this stock · 17 targets measuredBuytarget $95.00Oct 30, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 2, 2026 | Unknown AnalystLeerink PartnersNov 2, 2026 | BuyMaintained | $94.00↗ | article ↗ |
| Oct 30, 2026 | Robbie MarcusJ.P. MorganOct 30, 2026 | HoldReiterated | $85.00↗ | article ↗ |
| Oct 30, 2026 | Jonathan BlockStifel NicolausOct 30, 2026 | BuyReiterated | $95.00↗ | article ↗ |
| Oct 30, 2026 | Josh JenningsTD CowenOct 30, 2026 | BuyReiterated | $95.00↗ | article ↗ |
| Oct 30, 2026 | Jayson BedfordRaymond JamesOct 30, 2026 | BuyMaintained | $97.00↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 8, 2026 · 150 ratings
Embed this asset
<a href="https://perpequities.com/stocks/dxcm-perp"><img src="https://perpequities.com/badge/dxcm-perp.svg" width="240" height="64" alt="DXCM perpetuals · perpequities.com" loading="lazy"></a>